Hikke (4, 6%), asteni/ træthed (2, 9%), forhøjet ALAT (2, 8%), forstoppelse (2, 2%), hovedpine (2, 2%) og anorexi (2, 0%).
The most common adverse reactions reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving highly emetogenic chemotherapy were: hiccups (4.6%), asthenia/ fatigue (2.9%), ALT increased (2.8%), constipation (2.2%), headache (2.2%), and anorexia (2.0%).